Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testing E/I imbalance in autism with Bumetanide – randomized waitlist-control trial
2021-003514-39Phase 2
- Sponsor
- Gillberg Neuropsychiatry Centre
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bumetanide in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Gillberg Neuropsychiatry Centre. Primary endpoint: Improvement in emotion labeling task.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2021-003514-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003514-39.